ITCH抗体;ITCH Antibody—艾普蒂

The ITCH antibody targets the ITCH protein, a member of the HECT (Homologous to E6-AP C-Terminus) family of E3 ubiquitin ligases. ITCH plays a critical role in ubiquitination, a post-translational modification process that tags proteins for degradation via the proteasome or regulates their activity. Structurally, ITCH contains an N-terminal C2 domain, multiple WW domains for substrate recognition, and a catalytic HECT domain at the C-terminus. It is involved in diverse cellular processes, including apoptosis, autophagy, immune response, and cell signaling pathways (e.g., Notch, Wnt, and NF-κB). Dysregulation of ITCH is linked to diseases such as cancer, autoimmune disorders, and neurodegenerative conditions. For example, ITCH deficiency in mice leads to autoimmune inflammation and aberrant immune cell activation, while altered ITCH expression in humans is associated with tumor progression or suppression, depending on context. Antibodies against ITCH are essential tools for studying its expression, localization, and interaction partners in experimental models (e.g., Western blot, immunofluorescence, co-immunoprecipitation). They help elucidate its regulatory mechanisms in disease pathways and potential therapeutic targeting. Researchers often validate these antibodies for species cross-reactivity (human, mouse, rat) and specificity to avoid off-target effects. Commercial ITCH antibodies vary in clonality (monoclonal/polyclonal) and application suitability, requiring careful selection for experimental reproducibility.